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Nanomedicine for cancer therapy is a successful tool to diminish the side effect of 
chemotherapeutics such as paclitaxel (PTX). In this regard, Abraxane®, a human serum 
albumin (HSA)-based nanomedicine system has showed lesser side effects than Taxol®. 
However, the large-scale production of HSA protein is limited and expensive, which is 
traduced in a high cost of the treatments in clinical applications. Thus, the use of easily-
available alternative nanocarriers could increment the accessibility of patients to 
nanomedicine for cancer treatments. Casein is a low-cost protein able to self-assemble 
into micelles which could efficiently encapsulate PTX into their structure. In this work, 
the synthesis of chemically crosslinked casein micelles (CCM), used to prepare PTX-
based nanoformulations, is presented. CCM@PTX nanoformulations showed promising 
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results in vitro to be applied as nanomedicine for cancer therapy. Thus, the obtained 
nanoformulations are great candidates to be parenterally administered, accumulate in 
tumor by passive targeting without leakage of PTX in plasma and release the drug within 
the tumor microenvironment, in response to overexpressed proteases such as trypsin.
1. Introduction
One of the most used drugs for the chemotherapheutic treatment of various cancer is 
paclitaxel (PTX), in a formulation called Taxol®.[1] The administration of paclitaxel in 
chemotherapy is not selective for patients because it affects both normal and cancerous 
cells. Paclitaxel, a water insoluble drug, requires other excipients for its parenteral 
administration such as Cremofor®-EL and ethanol. This formulation shows severe 
adverse effects such as low blood counts, hair loss, peripheral sensory neuropathy, nausea 
and vomiting, arthralgia, myalgia and extremely hypersensitive reactions.[2] For this 
reason, with the aim of reducing such undesirable effects and increasing its therapeutic 
index, paclitaxel has been encapsulated in nanoparticles of different nature such as 
liposomes [3],[4], polymeric nano/microparticles [5],[6], micelles [7],[8], dendrimers 
[9],[10], among others. 
The encapsulation of paclitaxel in nanoparticles allows directing the drug towards the 
tumor by the enhanced permeability and retention effect (EPR), also named passive 
targeting, which was initially described by Maeda.[11] Passive targeting has increased 
the therapeutic index of paclitaxel, and decreased the doses and adverse effects of 
Taxol®. One of the products based on  nanomedicine and currently approved for use in 
humans is Abraxane®, consists in a nanoparticle formulation based on human serum 
albumin (HSA) that encapsulates paclitaxel using nanoparticle albumin bound (NAB)-
technology.[1] Another currently commercialized product is a liposomal formulation 
containing paclitaxel named Lipusu®, which was approved by the State Food and Drug 
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Administration of China. In addition, the commercialization of other nanosystems based 
on micelles from a block copolymer of polyethylene glycol (PEG) and polylactic acid 
(PLA), called Genexol-PM®, has recently been launched.[1] However, all these 
formulations exhibit problems of nanoparticles stability in blood, since they break into 
polymer units of lower molecular weight, producing a premature release of the drug in 
non-specific sites. A possible solution for this problem involves the use of nanovehicles 
with a crosslinked structure to increase their stability in the bloodstream. After parenteral 
administration of crosslinked nanoparticles, they can reach the tumor site without drug 
leakage and then deliver their payload only at the site of action, immediately after facing 
an environmental trigger. [12],[13],[14] 
After approving Abraxane® formulation for human administration, protein-based 
nanoparticles have received great interest for the encapsulation of PTX.[15–17] However, 
the high cost of large-scale production of HSA and consequently its use in carriers for 
cancer therapy, makes this type of products very expensive for the patient. Under this 
scenario, we have recently proposed the use of bovine casein micelles as alternative 
nanocarriers of therapeutic drugs.[18],[19] These low-cost vehicles have a hydrophobic 
core and a hydrophilic surface, present excellent stability in aqueous dispersion and allow 
for loading a large number of non-polar drugs.[18] In addition, this biodegradable and 
biocompatible protein has a great number of functional groups which could serve as 
anchoring points to yield reticulated networks and thus increase the stability of the 
micelles in dispersion. For this reason, casein is regarded as an excellent candidate as 
excipient for pharmaceutical applications in drug delivery.[20] Although other authors 
have previously reported the use of casein micelles (CM) as carriers for oral delivery of 
PTX in gastric carcinoma therapy [21–26], the parenteral application of this system in 
cancer therapy has not been reported in literature and could be of great interest for the 
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pharmaceutical industry. CM are of particular importance due to their nanometric size in 
dispersion for intracellular drug delivery. The hydrophilic shell of these nanovehicles 
composed of -casein, could mimic PEGylated nanoparticles which are reported to avoid 
opsonization.[27,28] In addition, CM can be easily degraded by proteolytic enzymes such 
as trypsin [18] or cathepsin B [29], which are overexpressed in several tumors. Taking 
into account these theoretical bases, this work proposes the development of stable 
chemically crosslinked casein micelles (CCM) that contain PTX into their hydrophobic 
pockets (CCM@PTX), obtaining a novel therapeutic nanoformulation. We prepared and 
characterized the CCM@PTX nanoformulations and demonstrate their potential to kill 
cancer cells after activate PTX release by action of trypsin. Thus, after parental 
administration, the CCM@PTX should be able to transport the anti-tumor drug through 
the bloodstream, conserving its payload and accumulating in the tumor by the EPR effect. 
Finally, CCM@PTX could be degraded by proteases in the tumor or intracellular 
microenvironment, releasing the drug and inhibiting the tumor progression. 
2. Experimental section
2.1. Materials and cell lines
The following chemicals were used as purchased: Caseinate sodium salt (CAS, Sigma-
Aldrich); N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 
Aldrich); N-hydroxysuccinimide (NHS, Aldrich); calcium chloride dihydrate 
(CaCl2.2H2O, Cicarelli); sodium chloride (NaCl, Cicarelli); acetic acid glacial (AA, 
Fisher Chemicals); sodium acetate (NaAc, Anedra); sodium dihydrogen phosphate 
(NaH2PO4, Anedra); disodium hydrogen phosphate (Na2HPO4, Anedra); rhodamine B 
(RhodB, Aldrich); 0.5% trypsin-EDTA (10X, Gibco); sodium azide (SA, Sigma-
Aldrich); sucrose (SC, Sigma-Aldrich); CellTiter 96® AQueous One Solution Cell 
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Proliferation Assay (MTS/PMS, Promega). Paclitaxel (PTX) was gently supplied by 
Eriochem S.A from Argentina. HeLa (ATCC® CCL-2™) and PC3 (ATCC® CRL-
1435™) cell lines were grown and maintained in Dulbecco´s Modified Eagle Medium 
(DMEM, Gibco) and Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 
(DMEM/F12, Gibco) supplemented with 10 % (v/v) fetal calf serum (FCS, Gibco) and 2 
mM glutamine (Gibco), respectively.
2.2 Preparation of CM 
CM were prepared according to our previously reported procedure.[18] Briefly, a solution 
of CAS (50 mg mL-1) was dialyzed against a 0.05 mM CaCl2 solution for 4 h using a 
dialysis membrane with molecular weight cut off (MWCO) of 10 kDa. After the dialysis 
process, re-assembled nanomicelles were kept at 4 °C for 48 h and then centrifuged at 
10,000 rpm for 10 min in order to eliminate protein aggregates. Finally, the CM were 
freeze-dried and stored at 4 °C for the posterior use.
2.3 Synthesis of CCM 
In a typical experiment, 40 mL of micelles aqueous dispersion (10 mg/mL) was pre-
heated at 70 °C for 10 min. After that, a mixture of EDC and NHS dissolved in 1 mL of 
water was added with the aim of producing crosslinking between NH2 and COOH groups 
of the CAS chains present in the re-assembled CM. Molar ratios of COOH:NHS:EDC = 
1:0.25:0.5 and 1:0.5:1 were used aiming to activate 25 and 50% of COOH groups per 
CAS molecule, respectively. For the calculation, the average molecular weight of casein 
was regarded 23 kDa as reported in literature [30] and the total number of COOH per 
molecule was 50, based on the aspartic and glutamic acids residues of this protein. The 
reaction was carried out at 70 °C for 4 h under stirring conditions. The obtained CCM 
were dialyzed against ultrapure water (4 changes of water) using a 50 kDa MWCO 
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membrane. The number of amine groups consumed after the reaction was determined by 
a colorimetric method using o-phthalaldehyde (OPA) as a fluorescent marker. The OPA 
method consists in the reaction of this reagent with primary amine groups of proteins to 
form highly fluorescent 1-alkylthio-2-alkyl substituted isoindoles, which show an 
absorption band at 340 nm. [31] For the analysis, 100 µL of CM dispersion (1 mg/mL) 
were mixed with 1 mL of freshly prepared OPA reagent (5 mg of OPA + 100 µL of pure 
ethanol + 5 µL of 2-mercatoethanol + 10 mL of 50 mM carbonate buffer pH 10.5). The 
absorbance was measured at 340 nm by UV-spectroscopy. The crosslinking efficiency 
was determined according to Eq. 1.
Crosslinking efficiency (%) = 100 x (ACCM – ACM)/ACM        (1)
where ACM and ACCM were the absorbance at 340 nm of CM and CCM samples, 
respectively. 
The samples were named CCM0.25 and CCM0.50 according to their theoretical degree 
of crosslinking. 
2.4. Scanning electron microscopy (SEM) 
The morphology of the CCM was studied by SEM using a Zeiss Sigma microscope. To 
this effect, samples were prepared by deposition of 10 L of CCM (0.001 mg mL-1) onto 
a silica sheet, covered after drying with chrome in a sputter coater, and observed under 
an accelerating voltage of 2.0 kV.
2.5 Dynamic light scattering (DLS) characterization
DLS was used to study the resistance of CCM against 0.1 M NaOH (pH 13), as 
dissociating agent, in order to confirm their crosslinking nature. Measurements were 
carried out using a Zetasizer Nano ZS (Malvern Instruments) at a scattering angle of 173° 
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and a laser wavelength of 633 nm. In order that, dispersions of CCM (10 mg mL-1) were 
diluted 1:5 in 0.01 M NaOH and the size distribution was determined. Non-crosslinked 
nanomicelles (CM) were used as control. In addition, the hydrodynamic diameters (Z-
average) and polydispersity index (PDI) of CCM under simulated physiological and 
intracellular conditions were also investigated by DLS. Re-dispersions of 1 mg mL-1 were 
prepared in 10 mM phosphate buffer pH 7.4 with 0.14 M NaCl (PBS), or 10 mM acetate 
buffer pH 5 with 0.14 M NaCl (ABS), and measured at 37 °C. Moreover, the degradation 
of the CCM by proteases was analyzed by DLS following the evolution of Derivate Count 
Rate (DCR) over time. Thus, CCM dispersions (5 mg mL-1) were diluted 1:5 in PBS (pH 
7.4), ABS (pH 5) or ABS (pH 5) plus trypsin (0.05 wt%).
2.6 PTX loading in CCM 
PTX was loaded in CCM by hydrophobic interactions. Briefly, a dispersion of CCM (5 
mg mL-1) was stirred with PTX previously dissolved in DMSO (10 or 20 wt% based on 
micelles) for 24 h. Next, micelles dispersion was dialyzed against water for 24 h (MWCO 
50 kDa, four replaces of solvent) to eliminate the free PTX and subsequently freeze-dried. 
The lyophilized powder was then re-dispersed in DMSO for 24 h to extract the loaded 
drug and centrifuged for the precipitation of the micelles. Finally, the extracted drug was 
quantified by high performance liquid chromatography (HPLC) using a Waters-Breeze 
chromatograph fitted with a Waters Symmetry C18 (5 mm, 4.6 × 150 mm) column and 
an UV photometer (Waters 2487). A solvent mixture of water/methanol/acetonitrile 
(25:11:64) was used as mobile phase at 1.0 mL min-1 rate. A 20 µL injection volume was 
used, and the PTX detection was performed at 227 nm. Calibration curve was performed 
using standard solutions of the following concentration: 2.5; 5; 10; 25; 40; 50; and 100 
ppm . The Drug Loading Content in the total formulation (%DLC) and the Drug Loading 
Efficiency (%DLE) were determined according to Eqs. 2 and 3, respectively: 
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DLC (wt %) = (WDL /WDLM) × 100        (2)
DLE (wt %) = (WDL /WF) × 100             (3)
where WDL is the weight of loaded drug, WDLM is the weight of drug-loaded CCM and 
WF is the weight of feeding drug.
The CCM@PTX nanoformulations were lyophilized in the dark and then maintained at 4 
°C for posterior utilization. The formulations were named CCM0.25@PTX10; 
CCM0.25@PTX20; CCM0.50@PTX10; and CCM0.50@PTX20. Samples redispersion 
was realized by sonication for 2 h at 37 °C. For the determination of the hydrodynamic 
diameter of the loaded samples after re-dispersion, DLS measurements were realized. In 
addition, the size stability of the CCM@PTX re-dispersions was followed for 7, 19 and 
72 h by DLS. 
2.7 Thermal analysis of CCM@PTX formulations 
The thermal stability of PTX, CCM and CCM@PTX in dry state was studied by 
thermogravimetric analysis (TGA) on a TGA Q500 thermobalance (TA Instruments). 
Samples (3 mg) were heated from 25 to 600 °C with a heating rate of 10 °C/min under 
nitrogen atmosphere (100 mL/min). Analysis by differential scanning calorimetry (DSC) 
was performed aiming to study the CCM/PTX interaction. Measurements were carried 
out with a heating rate of 5 °C/min from 25 to 320 °C employing a DSC Q2000 equipment 
(TA instruments). Dry samples of 8–10 mg were weighed and placed into a hermetic 
sealed aluminum pan (TZero Technology). Nitrogen was used as purging gas and the 
sample chamber flushed at a flow rate of 50 mL/min. Thermal transitions were 
determined using the TA Universal Analysis software.
2.8 Cellular uptake pathways 
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Different inhibitors were evaluated to study the endocytic uptake mechanisms of CCM. 
First CCM were labeled with rhodamine B (Rhod B) using EDC/NHS chemistry (the 
amines of CCM react with the NHS activated carboxylic acid of Rhod B). Then, the effect 
of the inhibitors was analyzed in HeLa and PC3 culture cells using CCM labeled with 
Rhod B (CCM-RhodB), as a reporter protein. Cells were seeded in 24-well plate (Greiner, 
Germany)  at a density of 1x105 cells per well and incubated at 37 °C for 24 h. The day 
of the study, cells were pre-incubated under different conditions in order to avoid 
endocytocis. Two inhibitors were tested at different concentrations: sodium azide (50; 
500 and 1000 µM) and sucrose (0.2; 0.45 and 0.6 M). Since incubation at 4 °C is meant 
to inhibit endocytocis, this condition was also evaluated. After 1 h of pre-treatment with 
the corresponding inhibitor, 0.01 mg mL-1 of CCM-RhodB were added to the cells and 
incubated for 2 h. Cells only treated with CCM-RhodB were included as control of 
internalization and cells without any treatment (CCM-RhodB and/or inhibitors) as the 
negative control. Adhered cells were washed 3 times with PBS 1X and analyzed by 
fluorescence microscopy (Olympus BX-51TRF, Olympus Optical Co. filters Ltd., Tokyo, 
Japan) equipped with a high-resolution camera (QImaging® Go-3, QImaging, Surrey, 
BC, Canada). Treatments were performed by duplicate and five pictures of each 
biological replicate, were taken, in order to perform the statistical analysis, using the same 
settings according to the excitation intensity. Images were processed by the plugins of 
Image J software to determine the mean fluorescence intensity (MFI). More than twenty 
cells per image were analyzed. Data collected was normalized with CCM-RhodB control 
and expressed as endocytosis inhibition percentage. Statistical analysis was carried out 
using one-way ANOVA followed by Dunnett´s test.
2.9 In vitro cell toxicity 
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In vitro cytotoxicity assays were performed in order to determine the non-toxic limit 
concentration (NLTC) of blank-CCM and the IC50 of CCM@PTX. Briefly, HeLa and 
PC3 cells were seeded into culture microtiter plates (Greiner, Germany) using growth 
medium at a density of 2.5x104 cells per well and incubated at 37 °C overnight. The 
culture supernatants were removed and serial dilutions of the samples CCM0.25 and 
CCM0.50 in growth medium were accomplished. CCM0.25 and CCM0.50 were 
evaluated in a concentration range from 0.5 to 0.008 mg mL-1 for both cell lines. PTX as 
well as CCM0.25@PTX10, CCM0.25@PTX20, CCM0.50@PTX10 and 
CCM0.50@PTX20 were evaluated from 100 nM to 0.8 nM of PTX for both cell lines. 
Cells without treatment were used as growth control. Plates were incubated at 37 °C for 
24 and 48 h. Cell proliferation was determined using a CellTiter 96TM AQueous Non-
Radioactive Cell Proliferation Assay (Promega). Absorbance was read at 492 and 690 nm 
using a microplate reader (MultiskanTM, Thermo Fisher Scientific). Absorbance of CCM 
was plotted against its concentration (mg mL-1). In the case of CCM loaded with PTX, 
plots of absorbance against PTX concentration (nM) were graphed. The IC50 was 
determined from CCM@PTX graphs as the concentration of the micelle that produces 
the dead of the fifty percent of the culture while NTLC was calculated for the blank-CCM 
as the highest concentration which produced the same color intensity than that of the 
negative control. The assays were carried out in four independent times and triplicates of 
the samples were evaluated in each test. Statistical analysis was carried out using 
Student´s t test or one-way ANOVA followed by Tukey´s post-test, accordingly. 
3. Results and Discussion
3.1 Preparation of CCM
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The CCM were prepared using the intrinsic properties of CAS to form micelles followed  
by a crosslinking process. Therefore, the synthesis of CCM was carried out through a 
two-step method as shown schematically in Figure 1. First, CM were re-assembled by 
dialysis in the presence of CaCl2.[18] In this step, the hydrodynamic diameter of the 
micelles formed was 163.3 nm (PDI = 0.116) as determined by DLS. After that, aiming 
to confer structural stability to the CM, an intra-micellar crosslinking reaction was 
performed between NH2 and COOH groups present in the protein molecule. As it is 
widely known, amines could react with acid groups that were previously activated by 
EDC/NHS chemistry. The crosslinking reaction was carried out at 70 °C since the PDI 
(0.086) of CM at this temperature was considerably lower than that at 25 °C (PDI= 0.228), 
as it was determined by DLS analysis under controlled temperature. CCM were obtained 
as a white dispersion after 4 h of reaction. As first evidence refereed to the effectiveness 
of the crosslinking reaction, the whitish dispersion obtained for CCM did not return to 
the most transparent white color of the CM after cooling at 25 °C. The number of amine 
groups consumed after the reaction determined by a colorimetric method using OPA as 
an fluorescent marker. Crosslinking  efficiencies of 21% and 50% were obtained for 
CCM0.25 and CCM0.5, respectively. 
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Figure 1. Schematic representation of CCM preparation. 
3.2 CCM stability determined by DLS 
In order to study the stability of the chemically crosslinked structure generated after 
micelles formation and amine/carboxylic acid intra-micellar reaction, the size 
distributions of the CCM were determined by DLS against 0.1 M NaOH (pH 13) as 
dissociating agent. Figure 2 shows the intensity-based size distribution of CCM0.50 in 
water or strong alkaline conditions, and compared with CM in the same media. 
As it can be observed, CCM resulted stable at pH 13 maintaining the size distribution 
with only small increase in the hydrodynamic diameter, probably due to the action of the 
dissociating agent which increases the swelling of the crosslinked structure. In contrast, 
CM were easily disassembled at pH 13, because the strong alkaline conditions disrupt the 
cohesive interactions between the hydrophobic region of the CAS.[32] CCM0.25 also 
showed high stability in alkaline medium as it can be observed in Figure S1 of the 
Supporting Information (SI). However, size distribution resulted broader for CCM0.25 
than for CCM0.5, which suggest that micelles present lower number of crosslinked points 
in accordance with the less amount of NHS/EDC couple used for their preparation (see 
Figure S2 in SI). These results show that CCM could be attractive as carriers in drug 
delivery for cancer therapy. Indeed, CCM could maintain the structural integrity in 
plasma conditions until achieving tumor tissue by EPR effect, thus preventing a 
premature drug release in a non-specific site. 
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Figure 2. Intensity-based size distribution of NonCM and CCM0.50 in water or alkaline 
conditions.
3.3 SEM characterization
The morphology of therapeutic nanocarriers is a key parameter to consider since it 
influences in their cellular uptake and penetration inside tumor tissue. Recent studies 
demonstrated that spherical nanoparticles show a significantly higher cell internalization 
than rods and vesicles.[33] Thus, the shape and size of CCM were analyzed by SEM. 
Figure 3 shows micrographies obtained for CCM0.50. As it can be observed, CCM 
present spherical morphology with a size of approximately 100 nm in dry state. 
a)                                                          b)
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Figure 3. Morphology of CCM0.50 observed by SEM at different magnifications.
3.4 Hydrodynamic diameter and enzymatic degradation of CCM in physiological media 
As it is known, the size and stability of nanoparticles under physiological salt 
concentrations and different pH conditions could define their utility as nanovehicles. The 
nanoparticle size is a crucial parameter that must be controlled to avoid the rapid 
clearance of the nanocarriers from the body by the reticuloendothelial system (RES) or 
by renal filtration. Thus, the hydrodynamic diameter of CCM was determined simulating 
the conditions that they would face during blood circulation and cellular internalization 
pathways. The micelles presented unimodal distributions (see Figures 4a and S3 of the 
SI) with similar diameters at both pH 7.4 and pH 5 (both under 0.14 M NaCl), without 
evidence of disintegration under these conditions. The mean sizes of CCM0.25 and 
CCM0.50 were 176.2 (PDI 0.101) and 190.0 nm (PDI 0.126) at pH 7.4; and 169.2 (PDI 
0.128) and 182.9 nm (PDI 0.119) at pH 5, respectively. A small increase in the size of 
both CCM was observed at pH 7.4 in comparison with pH 5, since micelles are probably 
more negatively ionized at nearly neutral pH (the isoelectric point of CAS is 4.6) inducing 
charge repulsion and producing an increased swelling of the network. However, the 
diameters of CCM at physiological pH and salt concentration are appropriated for their 
utilization in cancer therapy. As it is widely accepted for the scientific community, 
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nanoparticles with sizes below 5 nm are rapidly cleared by renal filtration, while sizes 
smaller than 200 nm are less phagocyted by the RES. 
Since casein-based micelles could be susceptible to proteases overexpressed in tumor 
microenvironment (TME) or intracellular conditions, the degradation capability using 
trypsin as model protease was analyzed. To this effect, the evolution of the derivate count 
rate  (DCR) of  micelles in dispersion, after enzyme addition, was followed over time by 
DLS.[34] As it can be observed in Figure 4b, the micelles were degraded immediately 
after the addition of trypsin in the medium, which is evidenced by the tremendous 
decrease of the DCR (light scattering intensity) from approximately 270000 to 70000 
kcps with almost not variations in the size of CCM (176.7 to 162.6 nm). These results 
suggest that under TME or cancer intracellular conditions, where proteases such as trypsin 
or cathepsin B are overexpressed, the enzyme activity could trigger an immediate release 
of any payload due to the disintegration of CCM structure. 
            a)
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             b)
Figure 4. a) Intensity-based size distribution of CCM0.50 in simulated physiological 
media at 37 °C; and b) evolution of the derived count rate of CCM0.50 after trypsin 
addition.
3.7 Loading of PTX within the CCM
The encapsulation of a highly hydrophobic drug, as PTX, in aqueous medium remains a 
challenge for nanocarriers engineering in pharmaceutical technology. In general, the 
nanocarrier should present a hydrophilic shell to interact with water and a hydrophobic 
core which could encapsulate the drug. In this regard, the amphiphilic nature of CCM, 
allows the effective encapsulation of PTX in aqueous dispersion as is schematically 
shown in Figure 5. 
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Figure 5. Schematic representation of PTX loading in CCM
After the addition of solid PTX to the CCM dispersion, the drug kept insoluble, but with 
24 h of stirring, it was completely dissolved by the interaction with the hydrophobic 
pockets of the protein. Stable formulations with % DLC of 10 or 20 were prepared 
reaching 100% of DLE, as determined by HPLC analysis. The micelles increased 180 
times the solubility of PTX in water (the solubility values of PTX in water and in CCM 
dispersion, are 0.00556 mg mL-1, and 1 mg mL-1, respectively). The re-dispersion of the 
micelles after lyophilization was performed by sonication. Thus, after 2 h of sonication 
at 37 °C, the micelles were able to recover their original size as was determined by DLS 
(Table 1).
Table 1: Hydrodynamic diameter of the micelles after lyophilization and 2 h of sonication 
for re-dispersion.









After loading and lyophilization process, the CCM@PTX formulations were analyzed by 
DSC in order to verify the interaction between CCM and PTX. The DSC thermogram of 
CCM0.25@PTX10 was compared with those from CCM0.25, pure PTX, and a physical 
mixture of CCM0.25 and PTX, as shown in Figure 6. As it can be observed, CCM0.25 
showed a glass transition temperature at 135 °C and a sharp endothermic peak at 153.1 
°C which correspond to thermal degradation of casein [35]. PTX presented an 
endothermic peak at 213 °C corresponding to its melting point. The physical mixture of 
CCM and PTX displayed similar peaks observed in the pure components with a sligth 
decrease in the PTX melting point (201 °C). However, for CCM@PTX formulation, the 
melting endothermic peak of PTX at 213 °C was not present, suggesting that the drug 
loading in CCM was effective. Similar results were observed for CCM0.50@PTX 
formulation (see Figure S4 of the SI). 
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Figure 6. DSC thermograms of CCM0.25@PTX10 formulation compared with non-
loaded CCM0.25, PTX and CCM0.25/PTX physical mixture. 
3.8 Cellular uptake pathways of CCM
Cellular uptake analysis of CCM-RhodB was studied by fluorescence microscopy in the 
cancer cell lines HeLa and PC3. Different endocytosis pathways were inhibited using 
varied conditions and inhibitor concentrations. So, different experimental conditions were 
used: sucrose, as an inhibitor of clathrin- mediated endocytosis; sodium azide, as an 
inhibitor of energy depending endocytocis endocytosis and temperature at 4 °C as an 
inhibitor of all energy-dependent pathways were used. Thus, fluorescence microscopy 
images were taken after incubation of cells with CCM-RhodB 0.01 mg mL-1 at different 
endocytosis inhibitor conditions, and the corresponding mean fluorescence intensity 
(MFI) was obtained. As it is shown in Figure 7a, the fluorescence intensity of the cells 
was notably reduced after 4 °C-incubation. The same effect was observed after incubation 
with increasing concentrations of sucrose and sodium azide. Those results evidence that 
inhibitors lower the entrance of CCM-RhodB to both cell lines. The MFI data obtained 
from the images were normalized to determine the percentage of endocytosis inhibition 
for each treatment. Thus, cells incubated only with CCM-RhodB (normal uptake control) 
were considered as 0% inhibition and the statistical analysis was performed (Figure 7b). 
The percentage of endocytosis inhibition was higher for PC3 cells reaching up to 60% 
values while the maximum inhibition percentage for HeLa cells was up to 40%. This 
result indicates that PC3 cells are more susceptible to the treatments. Sodium azide and 
sucrose treatments showed a dose-dependent inhibition effect for both cell lines. The 
different concentrations of both inhibitors used in this assay were previously analyzed to 
confirm that they are not toxic for PC3 and HeLa cells. Particularly, incubation at 4 °C 
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was also effective to reduce the entrance of CCM-RhodB to both cell lines. Specifically, 
for PC3 cells all the conditions studied showed statistical significance compared to the 
control (CCM-RhodB), while for HeLa cells only 4 °C, sodium azide 1000 µM and 
sucrose 0.45 and 0.6 M presented a significant inhibition effect. These results indicate 
that CCMs are uptaken by PC3 and HeLa cells through different endocytosis pathways. 
Particularly, the notable inhibition observed after the incubation of CCM-RhodB with 




Figure 7: Cellular uptake in HeLa and PC3 cells after incubation of CCM-RhodB and 
different endocytosis inhibitors for 2 h. a) Fluorescence microscopy images of HeLa and 
PC3 cells treated with CCM-RhodB in presence of different endocytosis inhibitors: 
temperature (4 °C); 0.2, 0.45, 0.6 M sucrose and 50, 500, 1000 µM sodium azide (SA). 
Negative control represents cells without any treatment. b) The MFI data from the images 
were normalized and used for the determination of the endocytosis inhibition percentage 
as: 100 - ((MFI sample/MFI control) *100). Statistical analysis was carried out using one-
way ANOVA followed by Dunnett´s test. * p<0.05; **p<0.01; ***p<0.001 represent the 
degree of statistical significance.
3.9 Cell viability 
Initially, in vitro biological assays were performed in order to determine the cytotoxicity 
of blank CCM against HeLa and PC3 cells, after 24 and 48 h of incubation. As it can be 
observed in Table 1a, CCM0.5 shows significantly higher toxicity than CCM0.25 for both 
cell lines (p˂0.05). Particularly, the NTLC of CCM0.5 corresponds to half of the value 
observed for CCM0.25 for both periods of incubation studied, indicating that the former 
is doubly toxic. This behavior could be attributed to the major degree of crosslinking 
which creates a more rigid structure for CCM0.5 diminishing their biodegradability and 
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affecting the cell viability. Later, the IC50 of CCM@PTX was studied on the same cell 
lines and periods of incubation. The IC50 was calculated considering the concentration 
of PTX (nM). To compare the toxicity between unloaded micelles and CCM@PTX, the 
concentration of the micelle (ng mL-1) corresponding to each IC50, was calculated. The 
result from the in vitro biological assays revealed that all the CCM@PTX exhibited 
cytotoxicity in a dose-dependent manner as well as free PTX. Besides, the NTLC of the 
blank CCM resulted in the order of µg mL-1 and the corresponding IC50 of loaded 
micelles (based on the IC50 regarding to the PTX content) resulted in the order of ng 
mL-1. So it could be confirmed that the toxicity of CCM@PTX is inherent to the PTX 
content and is not related with the composition of the micelles. After 24 h of incubation, 
it can be observed that HeLa cells are more susceptible to PTX than PC3, since the IC50 
is significantly lower in this cell line (p=0.0014), meaning that lower concentrations are 
enough to induce cytotoxicity. The statistical analysis of the results obtained after testing 
CCM@PTX in PC3 cells reveals that the nanoformulations are significantly more 
cytotoxic than free PTX (p˂0.05), except for CCM0.50@PTX20 that did not show 
significant differences after 24 h of incubation. In the case of HeLa cells, PTX loaded 
micelles resulted as cytotoxic as PTX (no significant differences). The only exception 
was CCM0.50@PTX20 since it showed lower cytotoxicity after 24 h of incubation. In 
general, if the PTX-loaded micelles were compared, the CCM0.25 seems to be more toxic 
than the CCM0.5 since their IC50 is inferior, meaning that a lower concentration of 
CCM0.25 can be used to induce cytotoxicity in both cell lines. Particularly, the IC50 of 
CCM0.25@PTX20 was significantly lower compared to CCM0.5@PTX20 (p˂0.05), 
supporting the idea mentioned above. This result might be due to the micelles 
composition and probably, the higher toxicity of CCM0.25 could be associated with a 
better release of PTX from the micelles than CCM0.5 because of the minor degree of 
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crosslinking points increases the degradability. Furthermore, comparing 
CCM0.25@PTX10 with CCM0.25@PTX20 pairs, the former exhibits higher 
cytotoxicity. This can be observed when comparing all the 10 and 20 CCM@PTX pairs. 
A certain difficulty for PTX release can be observed for the CCM containing a higher 
PTX loading. Taken together, the comparison of micelles with different characteristics, 
CCM0.25@PTX10 vs. CCM0.5@PTX20, revealed that the lower the crosslinking degree 
and the PTX loading, the higher the cytotoxicity (p<0.05) for both cell lines. Altogether, 
these results show the potential of the nanoformulations to be used in cancer therapy. 
Specifically, CCM0.25@PTX10 represents an interesting candidate since it can to induce 
cytotoxicity in PC3 and HeLa cells using the lowest concentration, and could reduce the 
side effects that this type of treatments could provoke in the patients.
Table 2: NTLC of CCM and IC50 of  CCM@PTX and free PTX in HeLa and PC3 cells 
after 24 and 48 h of incubation.
a) NTLC of unload CCM




CCM0.25 126 ± 25 78 ± 15
CCM0.5 64 ± 17 45 ± 25
24 h
CCM0.25 83 ± 29 167 ± 23
CCM0.5 38 ± 2 73 ± 6
48 h
b) IC50 of CCM@PTX and free PTX
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The IC50 of each sample (PTX and CCM@PTX) was calculated considering the 
concentration of PTX (nM). For each IC50 calculated in columns 2 and 3, the 
corresponding concentration of micelles in ng mL-1 was determined (*columns 4 and 5).
4. Conclusions
Crosslinked casein micelles (CCM) were effectively prepared in two steps with diameters 
of approximately 180 nm in dispersion and spherical morphology. An immediate 
degradability of the micelles against trypsin was observed by DLS.  The CCM were able 
to load 10 and 20 wt% of PTX in a simple procedure without compromising the 
Sample
IC50 of PTX and 
CCM@PTX (nM)




PC3 HeLa PC3 HeLa
PTX 11 ± 2  2 ± 1 - -
CCM0.25@PTX10 4.4 ± 0.1 3 ± 1 38 ± 1 26 ± 9
CCM0.5@PTX10 6.4 ± 0.3 5 ± 2 55 ± 3 43 ± 17
CCM0.25@PTX20 5 ± 1 5 ± 2 21 ± 4 21 ± 9
CCM0.5@PTX20 10 ± 2 8 ± 3 43 ± 9 34 ± 13
24 h
PTX 11 ± 2 8 ± 2 - -
CCM0.25@PTX10 4 ± 1 5 ± 1 34 ± 9 43 ± 9
CCM0.5@PTX10 3.4 ± 0.5 7 ± 2 29 ± 4 60 ± 17
CCM0.25@PTX20 5 ± 1 6 ± 1 21 ± 4 26 ± 4
CCM0.5@PTX20 6 ± 3 7.5 ± 0.3 26 ± 13 32 ± 1
48 h
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dispersability of the micelles. A good interaction between the micelles and PTX was 
shown by DSC analysis. The main pathway for cell uptaking of the CCM was the chlatrin 
mediated endocytosis, as demonstrated by fluorescence microscopy using different 
inhibitors. In, addition, cell toxicity studies in two cancer cell lines showed that the 
CCM@PTX formulations were more cytotoxic than free PTX. Thus, the 
nanoformulations could present potential for their parenteral administration with a 
posterior accumulation in tumor microenvironment by passive targeting (EPR effect) and 
producing enzyme-activated release of PTX to kill cancer cells. Finally, these preliminary 
results encourage us to think that the prepared low-cost nanomedicine could be an 
alternative in cancer therapy to the marketed Abraxane®.
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Highlights
- Cross-linked casein micelles (CCM) were prepared using casein self-assembly 
properties
- The CCM were degraded immediately after exposition to proteases
- The CCM were able to load paclitaxel (PTX) in their structure
- In vitro studies in models cells showed that CCM@PTX improve the toxicity of PTX
- CCM@PTX have potential for parenteral administration to treat cancers with proteases 
overexpression 
